(Total Views: 326)
Posted On: 07/21/2020 5:32:15 AM
Post# of 36564
Generex Biotechnology Shares Rise 7% on Pre-IND for Covid-19 Vaccine
7/20/20 9:41 AM ET (Dow Jones)Print
By Chris Wack
Generex Biotechnology Corp. shares rose 7% to 61 cents in early trade after the company said it has submitted a pre-investigational new drug briefing package to the U.S. Food and Drug Administration requesting regulatory guidance on the Phase I/II clinical trial protocol and clinical development plan for the Ii-Key-SARS-CoV-2 coronavirus prophylactic vaccine.
The company said the Ii-Key-SARS-CoV-2 peptide epitopes, which contain target amino acid sequences from the virus, will be screened against blood samples collected from Covid-19 convalescent patients to select those Ii-Key peptides that activate the immune system to fight the coronavirus infection.
The blood screening program, which is scheduled to begin next week, incorporates T Cell Assays, antibody screening and isolation, virus neutralization tests and a novel in-vitro "cytokine storm" cellular assay.
TDA Newsfeed
7/20/20 9:41 AM ET (Dow Jones)Print
By Chris Wack
Generex Biotechnology Corp. shares rose 7% to 61 cents in early trade after the company said it has submitted a pre-investigational new drug briefing package to the U.S. Food and Drug Administration requesting regulatory guidance on the Phase I/II clinical trial protocol and clinical development plan for the Ii-Key-SARS-CoV-2 coronavirus prophylactic vaccine.
The company said the Ii-Key-SARS-CoV-2 peptide epitopes, which contain target amino acid sequences from the virus, will be screened against blood samples collected from Covid-19 convalescent patients to select those Ii-Key peptides that activate the immune system to fight the coronavirus infection.
The blood screening program, which is scheduled to begin next week, incorporates T Cell Assays, antibody screening and isolation, virus neutralization tests and a novel in-vitro "cytokine storm" cellular assay.
TDA Newsfeed
(0)
(0)
